Piedmont Animal Health Achieves Second FDA Approval In Less Than 18 Months

Robust pipeline places company in position to be among top seven US companion animal veterinary pharmaceutical companies by 2020

GREENSBORO, N.C., –Piedmont Animal Health announces its second approval from the Food and Drug Administration for companion animals, new advantusTM (imidacloprid) soft chew, an oral flavored chewable flea medication for dogs.i The new animal drug application (NADA) is formulated in Piedmont’s patented soft chew invention, offering convenient, palatable dosing. The approval represents the second FDA approval for Piedmont and its first NADA approval. In June 2013, Piedmont announced the approval of quellinTM (carprofen) soft chews, an abbreviated new animal drug application (ANADA).ii

Rapid Product Development
“From start to finish, this product was developed on a rapid timeline, thanks to our talented and experienced team of professionals,” says Roland Johnson, Piedmont founder and CEO. “With more than 20 additional products in various stages of development, we expect a steady stream of new product approvals–some of which we project will be blockbusters once they are in the marketplace.”

Top Seven by 2020
Piedmont plans to commercialize more than 10 of its pipeline products, and, as with advantus, already holds out-licensing agreements with multiple global animal health pharmaceutical companies for the others. Based on independent market research, sales of Piedmont’s retained portfolio products are projected to reach $175 million annually by the end of 2020.iii “With a pipeline this rich, I fully anticipate that Piedmont will be among the top seven companion animal veterinary pharmaceutical companies in the U.S. in just over five years,” adds Johnson.

About Piedmont Animal Health
Piedmont Animal Health (part of Piedmont Pharmaceuticals) is led by a team of seasoned veterinary pharmaceutical innovators that has developed, launched, or marketed more than 20 companion animal health products. Today, these products represent approximately 25 percent of the total revenue in the U.S. small animal veterinary segment. A leader in innovation, Piedmont is dedicated to developing products that improve compliance and ease of use. For more information, visit PiedmontAnimalHealth.com and PiedmontPharma.com

i NADA 141-435, Approved by FDA
ii ANADA 200-555, Approved by FDA
iii Based on independent new product research conducted by AllPoints Research with 316 veterinary practices in Nov/Dec 2014